Dacarbazine News and Research

RSS
Patients with advanced Hodgkin's lymphoma may benefit from radiotherapy after chemotherapy

Patients with advanced Hodgkin's lymphoma may benefit from radiotherapy after chemotherapy

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

Phase 2 clinical study reports best outcomes to date for older Hodgkin lymphoma patients

Phase 2 clinical study reports best outcomes to date for older Hodgkin lymphoma patients

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Study reports longer survival for obese men with metastatic melanoma

Study reports longer survival for obese men with metastatic melanoma

New compound takes positive step toward creating drug for melanoma

New compound takes positive step toward creating drug for melanoma

Study addresses cost-effectiveness of checkpoint inhibitors for advanced melanoma in Hong Kong

Study addresses cost-effectiveness of checkpoint inhibitors for advanced melanoma in Hong Kong

Chemotherapy drug combination appears to increase production of eggs in women's ovaries

Chemotherapy drug combination appears to increase production of eggs in women's ovaries

Experts to analyse latest advances in diagnosis, treatment of soft tissue sarcoma at PharmaMar seminar

Experts to analyse latest advances in diagnosis, treatment of soft tissue sarcoma at PharmaMar seminar

Eisai's Halaven receives FDA approval for treatment of patients with metastatic liposarcoma

Eisai's Halaven receives FDA approval for treatment of patients with metastatic liposarcoma

Halaven (eribulin mesylate) approved for treatment of liposarcoma

Halaven (eribulin mesylate) approved for treatment of liposarcoma

Array BioPharma reports top-line results from binimetinib Phase 3 trial in patients with NRAS-mutant melanoma

Array BioPharma reports top-line results from binimetinib Phase 3 trial in patients with NRAS-mutant melanoma

FDA approves Yondelis (trabectedin) for treatment of specific soft tissue sarcomas

FDA approves Yondelis (trabectedin) for treatment of specific soft tissue sarcomas

Array Biopharma reports strong fourth quarter and full year 2015 financial results

Array Biopharma reports strong fourth quarter and full year 2015 financial results

Phase 3 SUMIT study: Selumetinib fails to meet primary endpoint in patients with metastatic uveal melanoma

Phase 3 SUMIT study: Selumetinib fails to meet primary endpoint in patients with metastatic uveal melanoma

Trabectedin may be better than dacarbazine for treatment of soft tissue sarcoma

Trabectedin may be better than dacarbazine for treatment of soft tissue sarcoma

Eisai Phase 3 trial of eribulin meets primary endpoint in patients with advanced soft tissue sarcoma

Eisai Phase 3 trial of eribulin meets primary endpoint in patients with advanced soft tissue sarcoma

Array BioPharma presents clinical data of BRAF, MEK and HER2 drugs at 2015 ASCO Annual Meeting

Array BioPharma presents clinical data of BRAF, MEK and HER2 drugs at 2015 ASCO Annual Meeting

Combination of anti-Nodal and DTIC therapy can produce anti-cancer effects

Combination of anti-Nodal and DTIC therapy can produce anti-cancer effects